Neurology | Home | MIMS Malaysia

Adding cilostazol to other antiplatelet agents could reduce post-CAS restenosis risk

Roshini Claire Anthony, Yesterday

Adding cilostazol to other antiplatelet agents could potentially reduce in-stent restenosis (ISR) among patients with carotid artery stenosis who undergo carotid artery stenting (CAS), according to results of the CAS-CARE* trial presented at ISC 2020.

Apixaban outperforms warfarin regardless of prior stroke, TIA, or TE

Elvira Manzano, Yesterday

Apixaban outperformed warfarin in preventing ischaemic events regardless of prior stroke, transient ischaemic attack (TIA), or thromboembolic event (TE) in patients with atrial fibrillation (AF) with recent acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI), a prespecified secondary analysis of the AUGUSTUS trial has shown.

Lower cholesterol targets after stroke may reduce subsequent major vascular events

3 days ago

Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.

Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes

04 May 2018

Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.

Adding cilostazol to other antiplatelet agents could reduce post-CAS restenosis risk

Roshini Claire Anthony, 31 Mar 2020

Apixaban outperforms warfarin regardless of prior stroke, TIA, or TE

Elvira Manzano, 31 Mar 2020

Is there a role for nerinetide following ischaemic stroke?

Roshini Claire Anthony, 25 Mar 2020

The eicosapeptide nerinetide did not improve outcomes in patients with large vessel occlusion-related acute ischaemic stroke who underwent endovascular thrombectomy (EVT). However, patients not treated with alteplase appeared to derive some benefit, results from the multinational ESCAPE-NA1* trial showed.

Could prompt tranexamic acid treatment reduce ICH growth?

Roshini Claire Anthony, 23 Mar 2020

Prompt treatment with tranexamic acid may reduce intracerebral haemorrhage (ICH) growth in patients with ongoing bleeding, though the timing of treatment appears to be key to improved outcomes, according to a study presented at ISC 2020.

0.25 mg/kg tenecteplase sufficient for large-vessel stroke

Pearl Toh, 19 Mar 2020

The lower 0.25 mg/kg dose of the thrombolytic tenecteplase may be sufficient for reperfusion of blocked vessels prior to thrombectomy in patients with ischaemic stroke due to large-vessel occlusion compared with the 0.4 mg/kg dose, according to the EXTEND-IA TNK* Part 2 study presented at the ISC 2020 Meeting.

Shingles vaccine may prevent strokes

Roshini Claire Anthony, 18 Mar 2020

Vaccination against herpes zoster (shingles) with the Zoster Vaccine Live (ZVL) vaccine may reduce the risk of stroke in older adults, according to a study presented at the recent ISC 2020 conference.

tPA before mechanical thrombectomy: To SKIP or not?

Elaine Soliven, 18 Mar 2020

Skipping intravenous (IV) tissue plasminogen activator (tPA) before mechanical thrombectomy (MT) may have similarly favourable outcomes to using tPA pre-MT in patients with acute stroke, according to the SKIP* study presented at ISC 2020.